AU2017365926B2 - Treatments for heart failure and cardiac ischaemic reperfusion injury - Google Patents

Treatments for heart failure and cardiac ischaemic reperfusion injury Download PDF

Info

Publication number
AU2017365926B2
AU2017365926B2 AU2017365926A AU2017365926A AU2017365926B2 AU 2017365926 B2 AU2017365926 B2 AU 2017365926B2 AU 2017365926 A AU2017365926 A AU 2017365926A AU 2017365926 A AU2017365926 A AU 2017365926A AU 2017365926 B2 AU2017365926 B2 AU 2017365926B2
Authority
AU
Australia
Prior art keywords
bar
shockwave
heart failure
heart
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2017365926A
Other languages
English (en)
Other versions
AU2017365926A1 (en
Inventor
Salomon Narodden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2017365926A1 publication Critical patent/AU2017365926A1/en
Application granted granted Critical
Publication of AU2017365926B2 publication Critical patent/AU2017365926B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017365926A 2016-11-24 2017-11-17 Treatments for heart failure and cardiac ischaemic reperfusion injury Expired - Fee Related AU2017365926B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619861.6A GB201619861D0 (en) 2016-11-24 2016-11-24 Treatments for heart failure and cardiac ischaemic reperfusion injury
GB1619861.6 2016-11-24
PCT/GB2017/053473 WO2018096319A1 (en) 2016-11-24 2017-11-17 Treatments for heart failure and cardiac ischaemic reperfusion injury

Publications (2)

Publication Number Publication Date
AU2017365926A1 AU2017365926A1 (en) 2019-07-04
AU2017365926B2 true AU2017365926B2 (en) 2025-06-05

Family

ID=58073526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017365926A Expired - Fee Related AU2017365926B2 (en) 2016-11-24 2017-11-17 Treatments for heart failure and cardiac ischaemic reperfusion injury

Country Status (16)

Country Link
US (1) US20190374623A1 (https=)
EP (1) EP3544624B1 (https=)
JP (1) JP7231543B2 (https=)
KR (1) KR102678011B1 (https=)
CN (1) CN109996558A (https=)
AU (1) AU2017365926B2 (https=)
CA (1) CA3044624A1 (https=)
ES (1) ES3017482T3 (https=)
GB (1) GB201619861D0 (https=)
HR (1) HRP20250664T1 (https=)
HU (1) HUE071244T2 (https=)
MY (1) MY200960A (https=)
PL (1) PL3544624T3 (https=)
RS (1) RS66778B9 (https=)
RU (1) RU2767445C2 (https=)
WO (1) WO2018096319A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023281447A1 (en) * 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
US20240122794A1 (en) * 2022-10-12 2024-04-18 Softwave Tissue Regeneration Technologies, Inc. Acoustic shock wave or pressure pulse treatment and methods of use for anti-aging
CN115998768B (zh) * 2023-02-07 2024-01-30 西南医科大学 M2型巨噬细胞外泌体在制备治疗心肌缺血再灌注损伤药物中的应用
CN117257785A (zh) * 2023-11-09 2023-12-22 新疆医科大学 没食子酸及其衍生物在制备预防和/或治疗心肌损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297470A1 (en) * 2006-04-19 2009-12-03 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2007416T3 (pl) * 2006-04-19 2018-05-30 Ludwig-Maximilians-Universität München Parathormon (PTH) do zastosowania w leczeniu niedokrwienia
MX2011009852A (es) * 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
EP3110449B1 (en) * 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297470A1 (en) * 2006-04-19 2009-12-03 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHINDA, K. et al. "Dipepidyl peptidase-4 Inhibitor Attenuated Ischemia-Reperfusion Injury via Preventing Mitochondrial Dysfunction and Reducing Cellular Apoptosis", Journal of the American College of Cardiology. March 2013. 61(10_Sup) E220. *
IHARA, M. et al. Am J Physiol Heart Circ Physiol. 2015 May 15;308(10):H1287-97. Epub 2015 Mar 6. *
ITO, Y. et al.: "Extracorporeal Cardiac Shock Wave Therapy Ameliorates Left Ventricular Remodeling after Myocardial lschemia Reperfusion Injury in Pigs", Circulation, October 2008. vol. 118, no. 18, Suppl. 2, Abstract 365, page S291. *
ITO, Y., "Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo." Coron Artery Dis. 2010 Aug;21(5):304-11. doi: 10.1097/mca.0b013e32833aec62. PMID: 20617568. *
SHIMOKAWA, H. et al. "Extracorporeal cardiac shock wave therapy for ischemic heart disease", Shock Waves 29 February 2008, vol. 17, no. 6, pages 449-455, ISSN: 1432-2153 DOI 10.1007/s00193-008-0122-5 *
TAKAHASHI, A. et al. "Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure overloaded mice", Am J Physiol Heart Circ Physiol. 2013 May 15;304(10):H1361-9. Epub 2013 Mar 15.. *
VAINER, J. et al. "Cardiac shockwave therapy in patients with chronic refractory angina pectoris", NETHERLANDS HEART JOURNAL, vol. 24, no. 5, 2 March 2016, pages 343-349, ISSN: 1568-5888, DOI: 10.1007/s12471-016-0821-y *
VASIUK, I.U. et al. "Efficacy of shock-wave therapy in the treatment of chronic ischemic heart failure]." Kardiologija 2010, vol. 50, no. 12, pages 22-26, ISSN: 0022-9040 *

Also Published As

Publication number Publication date
GB201619861D0 (en) 2017-01-11
RS66778B1 (sr) 2025-06-30
WO2018096319A1 (en) 2018-05-31
RU2767445C2 (ru) 2022-03-17
RU2019119110A3 (https=) 2021-08-30
JP2020510616A (ja) 2020-04-09
PL3544624T4 (pl) 2025-11-03
JP7231543B2 (ja) 2023-03-01
MY200960A (en) 2024-01-26
HUE071244T2 (hu) 2025-07-28
EP3544624C0 (en) 2025-02-12
HRP20250664T1 (hr) 2025-10-24
RU2019119110A (ru) 2020-12-24
KR20190100199A (ko) 2019-08-28
PL3544624T3 (pl) 2025-11-03
US20190374623A1 (en) 2019-12-12
KR102678011B1 (ko) 2024-06-25
EP3544624B1 (en) 2025-02-12
AU2017365926A1 (en) 2019-07-04
CA3044624A1 (en) 2018-05-31
ES3017482T3 (en) 2025-05-13
EP3544624A1 (en) 2019-10-02
RS66778B9 (sr) 2025-08-29
CN109996558A (zh) 2019-07-09

Similar Documents

Publication Publication Date Title
AU2017365926B2 (en) Treatments for heart failure and cardiac ischaemic reperfusion injury
US20090297470A1 (en) Remedies for ischemia
KR102778218B1 (ko) 심혈관 병태에서의 세마글루타이드
CN101939014A (zh) 亚硝酸盐在慢性缺血中的应用
JP2014533697A (ja) デフェリプロンを用いた処置方法
JP2013528649A (ja) 肺高血圧症の処置のために使用するためのラノラジン
KR102417455B1 (ko) 심혈관 질환에서의 리라글루티드
Kanemitsu et al. Insulin-like growth factor-1 enhances the efficacy of myoblast transplantation with its multiple functions in the chronic myocardial infarction rat model
US20030158247A1 (en) Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
CN1406132A (zh) 处理或抑制细胞损伤或细胞死亡的方法
US20170231946A1 (en) Cafestol for treating diabetes
CN119894507A (zh) 嵌合抗原受体（car）t细胞辅助疗法
US20070032557A1 (en) Method for administering levosimendan
JP2022516199A (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
Hoette et al. Dual receptor blockade by bosentan: clinical experience in treatment of pulmonary hypertension
JP6935930B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
Dulsat European Society of Cardiology (ESC) Congress 2019. Paris, France-August 31-September 4, 2019
Nikolaeva et al. Results of the Cardiological Study Invest: A New Word in the Therapy of Patients with Hypertension
WO2025164712A1 (ja) アドレノメデュリンの投与方法
Miyatake Impaired systolic torsion in dilated cardiomyopathy: Reversal of apical rotation at mid-systole characterized with
Scarlini et al. Effects of cholecalciferol supplementation in patients with low vitamin D levels and chronic heart failure-a randomized double blind controlled trial
Pastormerlo et al. P4025 Sympathetic renal denervation after acute myocardial infarction results in increased myocardial salvage in pigs
Di Nardo et al. Effects of a-human atria1 natriuretic peptide in guinea-pig isolated heart

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee